FDA Oral Contraceptives Guidance "Oversimplifies" Risk Information, J&J Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson is concerned that the draft guidance will not "objectively relate the risks" to physicians. The company also recommends including newer references for risk information.